STOCK TITAN
  1. Home
  2. Sec-filings
  3. PALI
  4. [Form 4/A] PALISADE BIO, INC. Amended Insider Trading Activity

PALI amends insider grant: 60,600 RSUs after rescinding 450,100

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Palisade Bio (PALI) filed a Form 4/A amending a prior equity grant for a director. The filing reports 60,600 restricted stock units (RSUs) granted on October 6, 2025, shown at a derivative security price of $0 with 60,600 derivative securities beneficially owned on a direct basis.

The amendment corrects a previously reported grant of 510,700 RSUs; the issuer has rescinded 450,100 of those RSUs. Each RSU represents a contingent right to one share, though RSUs may be settled in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan. The RSUs vest in three equal annual installments, with the first vesting on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025, subject to continuous service.

Positive

  • None.

Negative

  • None.
Insider Chuang Emil
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Units 60,600 $0.00 --
Holdings After Transaction: Restricted Stock Units — 60,600 shares (Direct)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan (the "Plan") to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. This amended Form 4 is being filed to correct the previously reported grant amount of 510,700 RSUs to the Reporting Person. The Issuer has rescinded the grant of 450,100 RSUs of the previously reported grant of 510,700 RSUs. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Chuang Emil
(Last) (First) (Middle)
1902 WRIGHT PLACE, SUITE 200
(Street)
CARLSBAD CA 92008
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PALISADE BIO, INC. [ PALI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
10/08/2025 		6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 10/06/2025 A 60,600(2) (3) (3) Common Stock 60,600 $0 60,600 D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan (the "Plan") to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash.
2. This amended Form 4 is being filed to correct the previously reported grant amount of 510,700 RSUs to the Reporting Person. The Issuer has rescinded the grant of 450,100 RSUs of the previously reported grant of 510,700 RSUs.
3. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date.
/s/ Ryker Willie, Attorney-in-Fact 11/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Palisade Bio (PALI) disclose in this Form 4/A?

An amended insider filing correcting an equity grant to a director to 60,600 RSUs as of October 6, 2025.

How many RSUs are reported after the amendment for PALI?

The filing shows a grant and beneficial ownership of 60,600 RSUs, held directly.

What change was made from the original RSU report for PALI?

A previously reported 510,700 RSU grant was corrected; 450,100 RSUs were rescinded.

What is the vesting schedule for the PALI RSUs?

They vest in three equal annual installments, first on the earlier of the 2026 annual meeting or the anniversary of October 6, 2025, subject to continuous service.

Can the PALI RSUs be settled in cash?

Yes. Until sufficient shares are reserved under the 2021 Equity Incentive Plan, RSUs may be settled in cash upon vesting.

What price is shown for the derivative security in the PALI filing?

The derivative security (RSUs) shows a price of $0.